ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NKTR vs OMER // FREE CASH FLOW YIELD

Nektar Therapeutics (NASDAQ) VS. Omeros Corporation (NASDAQ) • 15-METRIC TALLY: NKTR 1 — OMER 3
▲ FREE CASH FLOW YIELD LEADER: OMER
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NKTR VS. OMER) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NKTR OMER SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 96.00% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -15.60% -8.47% -7.13 OMER /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -43.90% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 1/9 +1.00 NKTR /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 35.2 52.9 -17.70 OMER /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.33B $1.33B -$7.7M OMER /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NKTR REV OMER REV NKTR GROSS % OMER GROSS % NKTR FCF OMER FCF
FY 2025 $55.2M $343.8M 98.0% — -$208.7M -$116.2M
FY 2024 $98.4M $467.5M 68.8% — -$177.2M -$149.0M
FY 2023 $90.1M — — — -$192.6M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NKTR // BETA —
OMER // BETA —